PDF DatasheetHuman Anti-CD147 / EMMPRIN / Neurothelin Antibody Product Attributes
CD147 / EMMPRIN / Neurothelin Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-BSG antibody staining is expected to be primarily localized to the vesicles.
Observed Antibody Staining Data By Tissue Type:
Variations in CD147 / EMMPRIN / Neurothelin antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the seminiferous ducts in testis, cells in the tubules in kidney, glandular cells in the colon, epididymis, rectum and stomach and trophoblastic cells in the placenta. More moderate antibody staining intensity was present in cells in the seminiferous ducts in testis, cells in the tubules in kidney, glandular cells in the colon, epididymis, rectum and stomach and trophoblastic cells in the placenta. Low, but measureable presence of CD147 / EMMPRIN / Neurothelin could be seen inepidermal cells in the skin, exocrine glandular cells in the pancreas, glandular cells in the adrenal gland and parathyroid gland, squamous epithelial cells in the cervix and uterine, tonsil and vagina. We were unable to detect CD147 / EMMPRIN / Neurothelin in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD147 / EMMPRIN / Neurothelin expression as measured by anti-CD147 / EMMPRIN / Neurothelin antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | + | ++ | + | + | ++ | + | + | ++ | ++ | ++ |
| BSG Variability | ++ | ++ | ++ | +++ | +++ | ++ | ++ | +++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| CD147 / EMMPRIN / Neurothelin General Information | |
|---|---|
| Alternate Names | |
| BSG, Basigin, Extracellular matrix metalloproteinase inducer, EMMPRIN, CD147, Cluster of Differentiation 147 | |
| Molecular Weight | |
| 35kDa (non-reduced); 40kDa (reduced) | |
| Chromosomal Location | |
| 19p13.3 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | BSG |
| Entrez Gene ID | 682 |
| Ensemble Gene ID | ENSG00000172270 |
| RefSeq Protein Accession(s) | NP_001719, NP_001309172, NP_940991, XP_016882662, NP_940992, NP_940993 |
| RefSeq mRNA Accession(s) | NM_001322243, NM_198589, NM_198591 NM_198590, NM_001728, XM_017027173 |
| RefSeq Genomic Accession(s) | NC_000019, NC_018930, NG_007468 |
| UniProt ID(s) | Q54A51, P35613 |
| UniGene ID(s) | Q54A51, P35613 |
| HGNC ID(s) | 1116 |
| Cosmic ID(s) | BSG |
| KEGG Gene ID(s) | hsa:682 |
| PharmGKB ID(s) | PA25433 |
| General Description of CD147 / EMMPRIN / Neurothelin. | |
| This MAb recognizes extracellular epitope 2 within the N-terminal Ig domain of human CD147. It is expressed more intensely on thymocytes than on mature peripheral blood T cells. CD147 is important in spermatogenesis, embryo implantation, neural network formation,, tumor progression. It stimulates the production of interstitial collagenase, gelatinase A, stromelysin-1, various metalloproteinases (MMPs) by fibroblasts. These enzymes are important factors in cancer invasion, metastasis. | |
There are no reviews yet.